î
îŒ
î
Unicycive Therapeutics Inc
UNCY6.180USD
+0.060+0.98%
çµå€Â 01/09, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
128.86Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± Unicycive Therapeutics Inc äŒæ¥å
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Unicycive Therapeutics Incã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãUNCY
äŒç€ŸåUnicycive Therapeutics Inc
äžå Žæ¥Jun 17, 2021
æé«çµå¶è²¬ä»»è
ãCEOãGupta (Shalabh)
åŸæ¥å¡æ°22
蚌åžçš®é¡Ordinary Share
決ç®ææ«Jun 17
æ¬ç€Ÿæåšå°4300 El Camino Real, Suite 210
éœåžLOS ALTOS
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·94022
é»è©±çªå·16503840642
ãŠã§ããµã€ãhttps://unicycive.com/
äŒæ¥ã³ãŒãUNCY
äžå Žæ¥Jun 17, 2021
æé«çµå¶è²¬ä»»è
ãCEOãGupta (Shalabh)
Unicycive Therapeutics Incã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
åçå èš³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Mon, Nov 17
æŽæ°æå»: Mon, Nov 17
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Vivo Capital, LLC
8.33%
Octagon Capital Advisors LP
4.65%
Nantahala Capital Management, LLC
4.37%
Great Point Partners, LLC
3.71%
The Vanguard Group, Inc.
3.07%
ä»ã®
75.88%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Vivo Capital, LLC
8.33%
Octagon Capital Advisors LP
4.65%
Nantahala Capital Management, LLC
4.37%
Great Point Partners, LLC
3.71%
The Vanguard Group, Inc.
3.07%
ä»ã®
75.88%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Hedge Fund
14.44%
Venture Capital
10.71%
Investment Advisor
3.40%
Individual Investor
2.93%
Investment Advisor/Hedge Fund
1.54%
Research Firm
0.29%
ä»ã®
66.69%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Thu, Jan 1
æŽæ°æå»: Thu, Jan 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q4
65
6.53M
30.38%
-306.64K
2025Q3
61
5.54M
31.38%
-1.91M
2025Q2
62
6.96M
54.51%
-655.75K
2025Q1
65
6.78M
64.49%
-1.12M
2024Q4
62
69.04M
66.51%
+542.97K
2024Q3
57
54.12M
55.45%
+17.71M
2024Q2
48
26.33M
50.66%
-3.75M
2024Q1
46
28.58M
99.15%
+4.37M
2023Q4
45
24.82M
96.62%
+1.55M
2023Q3
47
22.73M
96.91%
+9.25M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Vivo Capital, LLC
1.79M
8.33%
+652.90K
+57.42%
Sep 30, 2025
Octagon Capital Advisors LP
1.00M
4.65%
--
--
Sep 30, 2025
Nantahala Capital Management, LLC
939.20K
4.37%
--
--
Sep 30, 2025
Great Point Partners, LLC
796.56K
3.71%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
658.88K
3.07%
+52.92K
+8.73%
Sep 30, 2025
Gupta (Shalabh K)
597.25K
2.78%
-100.00
-0.02%
Apr 30, 2025
Logos Global Management LP
473.56K
2.2%
+1.00
+0.00%
Sep 30, 2025
Rosalind Advisors, Inc.
242.49K
1.13%
+242.49K
--
Apr 30, 2025
Geode Capital Management, L.L.C.
125.73K
0.58%
+66.94K
+113.87%
Sep 30, 2025
Squarepoint Capital LLP
117.33K
0.55%
+117.33K
--
Sep 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
æ¯ç0%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
Jun 17, 2025
Merger
10â1
æ¥ä»
çš®é¡
æ¯ç
Jun 17, 2025
Merger
10â1
ãããã質å
Unicycive Therapeutics Incã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îUnicycive Therapeutics Incã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
Vivo Capital, LLCã¯1.79Mæ ªãä¿æããŠãããããã¯å šäœã®8.33%ã«çžåœããŸãã
Octagon Capital Advisors LPã¯1.00Mæ ªãä¿æããŠãããããã¯å šäœã®4.65%ã«çžåœããŸãã
Nantahala Capital Management, LLCã¯939.20Kæ ªãä¿æããŠãããããã¯å šäœã®4.37%ã«çžåœããŸãã
Great Point Partners, LLCã¯796.56Kæ ªãä¿æããŠãããããã¯å šäœã®3.71%ã«çžåœããŸãã
The Vanguard Group, Inc.ã¯658.88Kæ ªãä¿æããŠãããããã¯å šäœã®3.07%ã«çžåœããŸãã
Vivo Capital, LLCã¯1.79Mæ ªãä¿æããŠãããããã¯å šäœã®8.33%ã«çžåœããŸãã
Octagon Capital Advisors LPã¯1.00Mæ ªãä¿æããŠãããããã¯å šäœã®4.65%ã«çžåœããŸãã
Nantahala Capital Management, LLCã¯939.20Kæ ªãä¿æããŠãããããã¯å šäœã®4.37%ã«çžåœããŸãã
Great Point Partners, LLCã¯796.56Kæ ªãä¿æããŠãããããã¯å šäœã®3.71%ã«çžåœããŸãã
The Vanguard Group, Inc.ã¯658.88Kæ ªãä¿æããŠãããããã¯å šäœã®3.07%ã«çžåœããŸãã
Unicycive Therapeutics Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
îUnicycive Therapeutics Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
Vivo Capital, LLC
Octagon Capital Advisors LP
Nantahala Capital Management, LLC
Vivo Capital, LLC
Octagon Capital Advisors LP
Nantahala Capital Management, LLC
Unicycive Therapeutics IncïŒUNCYïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q4æç¹ã§ãUnicycive Therapeutics Incã®æ ªåŒãä¿æããŠããæ©é¢ã¯65瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ6.53Mã§ãå
šäœã®30.38%ãå ããŠããŸãã2025Q3ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯-1.00%å¢å ããŠããŸãã
Unicycive Therapeutics Incã®æ倧ã®åçæºã¯äœã§ããïŒ
î--ã«ãããŠã--éšéãUnicycive Therapeutics Incã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯--ã§ãå
šåçã®--%ãå ããŠããŸãã
